<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36717478</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Bicalutamide and Trehalose Ameliorate Spinal and Bulbar Muscular Atrophy Pathology in Mice.</ArticleTitle><Pagination><StartPage>524</StartPage><EndPage>545</EndPage><MedlinePgn>524-545</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-023-01343-x</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA) is characterized by motor neuron (MN) degeneration that leads to slowly progressive muscle weakness. It is considered a neuromuscular disease since muscle has a primary role in disease onset and progression. SBMA is caused by a CAG triplet repeat expansion in the androgen receptor (AR) gene. The translated poly-glutamine (polyQ) tract confers a toxic gain of function to the mutant AR altering its folding, causing its aggregation into intracellular inclusions, and impairing the autophagic flux. In an in vitro SBMA neuronal model, we previously showed that the antiandrogen bicalutamide and trehalose, a natural disaccharide stimulating autophagy, block ARpolyQ activation, reduce its nuclear translocation and toxicity and facilitate the autophagic degradation of cytoplasmic AR aggregates. Here, in a knock-in SBMA mouse model (KI AR113Q), we show that bicalutamide and trehalose ameliorated SBMA pathology. Bicalutamide reversed the formation of the AR insoluble forms in KI AR113Q muscle, preventing autophagic flux blockage. We demonstrated that apoptosis is activated in KI AR113Q muscle, and that both compounds prevented its activation. We detected a decrease of mtDNA and an increase of OXPHOS enzymes, already at early symptomatic stages; these alterations were reverted by trehalose. Overall, bicalutamide and/or trehalose led to a partial recovery of muscle morphology and function, and improved SBMA mouse motor behavior, inducing an extension of their survival. Thus, bicalutamide and trehalose, by counteracting ARpolyQ toxicity in skeletal muscle, are valuable candidates for future clinical trials in SBMA patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galbiati</LastName><ForeName>Mariarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy. rita.galbiati@unimi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meroni</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boido</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience Rita Levi Montalcini, Neuroscience Institute Cavalieri Ottolenghi, University of Turin, Orbassano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cescon</LastName><ForeName>Matilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusmini</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crippa</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristofani</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccolella</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedesco</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casarotto</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chierichetti</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cozzi</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mina</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicardi</LastName><ForeName>Maria Elena</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Vickie and Jack Farber Institute for Neuroscience, Weinberg ALS Center, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedretti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitro</LastName><ForeName>Nico</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caretto</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience Rita Levi Montalcini, Neuroscience Institute Cavalieri Ottolenghi, University of Turin, Orbassano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ris&#xe8;</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmaceutiche, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmaceutiche, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonaldo</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pennuto</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veneto Institute of Molecular Medicine (VIMM), Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vercelli</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience Rita Levi Montalcini, Neuroscience Institute Cavalieri Ottolenghi, University of Turin, Orbassano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8883-0468</Identifier><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza 2018-2027, Universit&#xe0; degli Studi di Milano, Milan, Italy. angelo.poletti@unimi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS114007</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>A0Z3NAU9DP</RegistryNumber><NameOfSubstance UI="C053541">bicalutamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>B8WCK70T7I</RegistryNumber><NameOfSubstance UI="D014199">Trehalose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000813">Anilides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014199" MajorTopicYN="N">Trehalose</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000813" MajorTopicYN="N">Anilides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Androgen receptor</Keyword><Keyword MajorTopicYN="N">Autophagy</Keyword><Keyword MajorTopicYN="N">Motor neuron</Keyword><Keyword MajorTopicYN="N">SBMA</Keyword><Keyword MajorTopicYN="N">Skeletal muscle</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>30</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36717478</ArticleId><ArticleId IdType="pmc">PMC10121997</ArticleId><ArticleId IdType="doi">10.1007/s13311-023-01343-x</ArticleId><ArticleId IdType="pii">10.1007/s13311-023-01343-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grunseich C, Fischbeck KH. Molecular pathogenesis of spinal bulbar muscular atrophy (Kennedy's disease) and avenues for treatment. Curr Opin Neurol. 2020;33(5):629&#x2013;634. doi: 10.1097/WCO.0000000000000856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000856</ArticleId><ArticleId IdType="pmc">PMC7748295</ArticleId><ArticleId IdType="pubmed">32773451</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold FJ, Merry DE. Molecular mechanisms and therapeutics for SBMA/Kennedy's disease. Neurotherapeutics. 2019;16(4):928&#x2013;947. doi: 10.1007/s13311-019-00790-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00790-9</ArticleId><ArticleId IdType="pmc">PMC6985201</ArticleId><ArticleId IdType="pubmed">31686397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Ling SC, Guo LT, Hung G, Tsunemi T, Ly L, et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron. 2014;82(2):295&#x2013;307. doi: 10.1016/j.neuron.2014.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.03.001</ArticleId><ArticleId IdType="pmc">PMC4096235</ArticleId><ArticleId IdType="pubmed">24742458</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray AL, Annan L, Dick JRT, La Spada AR, Hanna MG, Greensmith L, et al. Deterioration of muscle force and contractile characteristics are early pathological events in spinal and bulbar muscular atrophy mice. Dis Model Mech. 2020;13(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272358</ArticleId><ArticleId IdType="pubmed">32152060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan CL, Lieberman AP. Spinal and bulbar muscular atrophy: a motoneuron or muscle disease? Curr Opin Pharmacol. 2008;8(6):752&#x2013;758. doi: 10.1016/j.coph.2008.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2008.08.006</ArticleId><ArticleId IdType="pmc">PMC2603477</ArticleId><ArticleId IdType="pubmed">18775514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Yu Z, Murray S, Peralta R, Low A, Guo S, et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014;7(3):774&#x2013;784. doi: 10.1016/j.celrep.2014.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.02.008</ArticleId><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Nirmalananthan N, Masset L, Skorupinska I, Collins T, Cortese A, et al. Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology. 2014;82(23):2077&#x2013;2084. doi: 10.1212/WNL.0000000000000507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000507</ArticleId><ArticleId IdType="pmc">PMC4075620</ArticleId><ArticleId IdType="pubmed">24814851</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front Neuroendocrinol. 2004;25(1):1&#x2013;26. doi: 10.1016/j.yfrne.2004.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2004.03.001</ArticleId><ArticleId IdType="pubmed">15183036</ArticleId></ArticleIdList></Reference><Reference><Citation>Vegeto E, Villa A, Della Torre S, Crippa V, Rusmini P, Cristofani R, et al. The role of sex and sex hormones in neurodegenerative diseases. Endocr Rev. 2020;41(2):273&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156855</ArticleId><ArticleId IdType="pubmed">31544208</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Soraru G, Pradat PF. Kennedy disease (X-linked recessive bulbospinal neuronopathy): a comprehensive review from pathophysiology to therapy. Rev Neurol (Paris) 2017;173(5):326&#x2013;337. doi: 10.1016/j.neurol.2017.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.03.019</ArticleId><ArticleId IdType="pubmed">28473226</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005;128(Pt 3):659&#x2013;670. doi: 10.1093/brain/awh381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh381</ArticleId><ArticleId IdType="pubmed">15659427</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35(5):843&#x2013;854. doi: 10.1016/S0896-6273(02)00834-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00834-6</ArticleId><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet. 2002;11(17):1967&#x2013;1976. doi: 10.1093/hmg/11.17.1967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/11.17.1967</ArticleId><ArticleId IdType="pubmed">12165558</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, Finkbeiner S, et al. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2009;18(11):1937&#x2013;1950. doi: 10.1093/hmg/ddp115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp115</ArticleId><ArticleId IdType="pmc">PMC2678926</ArticleId><ArticleId IdType="pubmed">19279159</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie HL, Pestell RG, Merry DE. SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. J Neurosci. 2011;31(48):17425&#x2013;17436. doi: 10.1523/JNEUROSCI.3958-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3958-11.2011</ArticleId><ArticleId IdType="pmc">PMC6088793</ArticleId><ArticleId IdType="pubmed">22131404</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua JP, Lieberman AP. Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy. CNS Neurol Disord Drug Targets. 2013;12(8):1146&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003563</ArticleId><ArticleId IdType="pubmed">24040817</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicardi ME, Cristofani R, Crippa V, Ferrari V, Tedesco B, Casarotto E, et al. Autophagic and proteasomal mediated removal of mutant androgen receptor in muscle models of spinal and bulbar muscular atrophy. Front Endocrinol. 2019;10:569. doi: 10.3389/fendo.2019.00569.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00569</ArticleId><ArticleId IdType="pmc">PMC6710630</ArticleId><ArticleId IdType="pubmed">31481932</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Crippa V, Cristofani R, Rinaldi C, Cicardi ME, Galbiati M, et al. The role of the protein quality control system in SBMA. J Mol Neurosci. 2016;58(3):348&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">26572535</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Crippa V, Giorgetti E, Boncoraglio A, Cristofani R, Carra S, et al. Clearance of the mutant androgen receptor in motoneuronal models of spinal and bulbar muscular atrophy. Neurobiol Aging. 2013;34(11):2585&#x2013;2603. doi: 10.1016/j.neurobiolaging.2013.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.05.026</ArticleId><ArticleId IdType="pmc">PMC3748343</ArticleId><ArticleId IdType="pubmed">23810450</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang MG, Gwak DW, Cho HJ, Min YS, Park JS. Effect of leuprorelin in bulbar function of spinal and bulbar muscular atrophy patients: observational study for 1 year. J Neurol. 2021;268(9):3344&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">33675422</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 2003;9(6):768&#x2013;773. doi: 10.1038/nm878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm878</ArticleId><ArticleId IdType="pubmed">12754502</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(9):875&#x2013;884. doi: 10.1016/S1474-4422(10)70182-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70182-4</ArticleId><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, Hirakawa A, Hijikata Y, Yamada S, et al. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. J Neurol Neurosurg Psychiatry. 2017;88(12):1026&#x2013;1032. doi: 10.1136/jnnp-2017-316015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316015</ArticleId><ArticleId IdType="pubmed">28780536</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr CR, Montie HL, Liu Y, Bolzoni E, Jenkins SC, Wilson EM, et al. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem. 2010;285(46):35567&#x2013;35577. doi: 10.1074/jbc.M110.146845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.146845</ArticleId><ArticleId IdType="pmc">PMC2975181</ArticleId><ArticleId IdType="pubmed">20826791</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier KJ, Troxell-Smith SM, Johansen JA, Katsuno M, Adachi H, Sobue G, et al. Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy. Endocrinology. 2014;155(7):2624&#x2013;2634. doi: 10.1210/en.2013-1756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2013-1756</ArticleId><ArticleId IdType="pmc">PMC4060177</ArticleId><ArticleId IdType="pubmed">24742193</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):140&#x2013;147. doi: 10.1016/S1474-4422(10)70321-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70321-5</ArticleId><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgetti E, Rusmini P, Crippa V, Cristofani R, Boncoraglio A, Cicardi ME, et al. Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy. Hum Mol Genet. 2015;24(1):64&#x2013;75. doi: 10.1093/hmg/ddu419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu419</ArticleId><ArticleId IdType="pmc">PMC4262493</ArticleId><ArticleId IdType="pubmed">25122660</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9(9):1308&#x2013;1320. doi: 10.4161/auto.25188.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.25188</ArticleId><ArticleId IdType="pubmed">23851366</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 2006;15(1):23&#x2013;31. doi: 10.1093/hmg/ddi422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi422</ArticleId><ArticleId IdType="pubmed">16311254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Chigurupati S, Raymick J, Mann D, Bowyer JF, Schmitt T, et al. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model. Neurotoxicology. 2014;44:250&#x2013;262. doi: 10.1016/j.neuro.2014.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2014.07.006</ArticleId><ArticleId IdType="pubmed">25064079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med. 2004;10(2):148&#x2013;154. doi: 10.1038/nm985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm985</ArticleId><ArticleId IdType="pubmed">14730359</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Cortese K, Crippa V, Cristofani R, Cicardi ME, Ferrari V, et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy. 2019;15(4):631&#x2013;651. doi: 10.1080/15548627.2018.1535292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2018.1535292</ArticleId><ArticleId IdType="pmc">PMC6526812</ArticleId><ArticleId IdType="pubmed">30335591</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, et al. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest. 2006;116(10):2663&#x2013;2672. doi: 10.1172/JCI28773..</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI28773.</ArticleId><ArticleId IdType="pmc">PMC1564432</ArticleId><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>Madeira JLO, Souza ABC, Cunha FS, Batista RL, Gomes NL, Rodrigues AS, et al. A severe phenotype of Kennedy disease associated with a very large CAG repeat expansion. Muscle Nerve. 2018;57(1):E95&#x2013;E97. doi: 10.1002/mus.25952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25952</ArticleId><ArticleId IdType="pubmed">28877561</ArticleId></ArticleIdList></Reference><Reference><Citation>Boido M, De Amicis E, Valsecchi V, Trevisan M, Ala U, Ruegg MA, et al. Increasing agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy. Front Cell Neurosci. 2018;12:17. doi: 10.3389/fncel.2018.00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00017</ArticleId><ArticleId IdType="pmc">PMC5797594</ArticleId><ArticleId IdType="pubmed">29440993</ArticleId></ArticleIdList></Reference><Reference><Citation>Boido M, Piras A, Valsecchi V, Spigolon G, Mareschi K, Ferrero I, et al. Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis. Cytotherapy. 2014;16(8):1059&#x2013;1072. doi: 10.1016/j.jcyt.2014.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2014.02.003</ArticleId><ArticleId IdType="pubmed">24794182</ArticleId></ArticleIdList></Reference><Reference><Citation>Furr BJ, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology. 1996;47(1A Suppl):13&#x2013;25. doi: 10.1016/S0090-4295(96)80003-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(96)80003-3</ArticleId><ArticleId IdType="pubmed">8560673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotfi P, Tse DY, Di Ronza A, Seymour ML, Martano G, Cooper JD, et al. Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency. Autophagy. 2018;14(8):1419&#x2013;1434. doi: 10.1080/15548627.2018.1474313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2018.1474313</ArticleId><ArticleId IdType="pmc">PMC6103706</ArticleId><ArticleId IdType="pubmed">29916295</ArticleId></ArticleIdList></Reference><Reference><Citation>Oesterreicher TJ, Markesich DC, Henning SJ. Cloning, characterization and mapping of the mouse trehalase (Treh) gene. Gene. 2001;270(1&#x2013;2):211&#x2013;220. doi: 10.1016/S0378-1119(01)00474-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-1119(01)00474-7</ArticleId><ArticleId IdType="pubmed">11404018</ArticleId></ArticleIdList></Reference><Reference><Citation>White RB, Bierinx AS, Gnocchi VF, Zammit PS. Dynamics of muscle fibre growth during postnatal mouse development. BMC Dev Biol. 2010;10:21. doi: 10.1186/1471-213X-10-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-213X-10-21</ArticleId><ArticleId IdType="pmc">PMC2836990</ArticleId><ArticleId IdType="pubmed">20175910</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R, Soraru G, Grunseich C, Fratta P, Zuccaro E, Pennuto M, et al. Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease. J Neurol Neurosurg Psychiatry. 2018;89(8):808&#x2013;812. doi: 10.1136/jnnp-2017-316961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316961</ArticleId><ArticleId IdType="pmc">PMC6204939</ArticleId><ArticleId IdType="pubmed">29353237</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Halievski K, Henley C, Atchison WD, Katsuno M, Adachi H, et al. Defects in neuromuscular transmission may underlie motor dysfunction in spinal and bulbar muscular atrophy. J Neurosci. 2016;36(18):5094&#x2013;5106. doi: 10.1523/JNEUROSCI.3485-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3485-15.2016</ArticleId><ArticleId IdType="pmc">PMC4854970</ArticleId><ArticleId IdType="pubmed">27147661</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia D, Malena A, Spinazzi M, Desbats MA, Salviati L, Russell AP, et al. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. Hum Mol Genet. 2017;26(6):1087&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409076</ArticleId><ArticleId IdType="pubmed">28087734</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A, Milioto C, Parodi S, Armirotti A, Borgia D, Pellegrini M, et al. Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathol. 2016;132(1):127&#x2013;144. doi: 10.1007/s00401-016-1550-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1550-4</ArticleId><ArticleId IdType="pmc">PMC4911374</ArticleId><ArticleId IdType="pubmed">26971100</ArticleId></ArticleIdList></Reference><Reference><Citation>Malacarne C, Galbiati M, Giagnorio E, Cavalcante P, Salerno F, Andreetta F, et al. Dysregulation of muscle-specific MicroRNAs as common pathogenic feature associated with muscle atrophy in ALS, SMA and SBMA: evidence from animal models and human patients. Int J Mol Sci. 2021;22(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8198536</ArticleId><ArticleId IdType="pubmed">34073630</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Polanco MJ, Cristofani R, Cicardi ME, Meroni M, Galbiati M, et al. Aberrant autophagic response in the muscle of a knock-in mouse model of spinal and bulbar muscular atrophy. Sci Rep. 2015;5:15174. doi: 10.1038/srep15174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15174</ArticleId><ArticleId IdType="pmc">PMC4614888</ArticleId><ArticleId IdType="pubmed">26490709</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Miranda HC, Frankowski H, Batlevi Y, Young JE, Le A, et al. Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat Neurosci. 2014;17(9):1180&#x2013;1189. doi: 10.1038/nn.3787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3787</ArticleId><ArticleId IdType="pmc">PMC4180729</ArticleId><ArticleId IdType="pubmed">25108912</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Wang AM, Adachi H, Katsuno M, Sobue G, Yue Z, et al. Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice. PLoS Genet. 2011;7(10):e1002321. doi: 10.1371/journal.pgen.1002321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002321</ArticleId><ArticleId IdType="pmc">PMC3192827</ArticleId><ArticleId IdType="pubmed">22022281</ArticleId></ArticleIdList></Reference><Reference><Citation>Adriaenssens E, Tedesco B, Mediani L, Asselbergh B, Crippa V, Antoniani F, et al. BAG3 Pro209 mutants associated with myopathy and neuropathy relocate chaperones of the CASA-complex to aggresomes. Sci Rep. 2020;10(1):8755. doi: 10.1038/s41598-020-65664-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-65664-z</ArticleId><ArticleId IdType="pmc">PMC7260189</ArticleId><ArticleId IdType="pubmed">32472079</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofani R, Crippa V, Cicardi ME, Tedesco B, Ferrari V, Chierichetti M, et al. A crucial role for the protein quality control system in motor neuron diseases. Front Aging Neurosci. 2020;12:191. doi: 10.3389/fnagi.2020.00191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00191</ArticleId><ArticleId IdType="pmc">PMC7385251</ArticleId><ArticleId IdType="pubmed">32792938</ArticleId></ArticleIdList></Reference><Reference><Citation>Arndt V, Dick N, Tawo R, Dreiseidler M, Wenzel D, Hesse M, et al. Chaperone-assisted selective autophagy is essential for muscle maintenance. Curr Biol. 2010;20(2):143&#x2013;148. doi: 10.1016/j.cub.2009.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2009.11.022</ArticleId><ArticleId IdType="pubmed">20060297</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V, Carra S, Rusmini P, Sau D, Bolzoni E, Bendotti C, et al. A role of small heat shock protein B8 (HspB8) in the autophagic removal of misfolded proteins responsible for neurodegenerative diseases. Autophagy. 2010;6(7):958&#x2013;960. doi: 10.4161/auto.6.7.13042.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.6.7.13042</ArticleId><ArticleId IdType="pubmed">20699640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandri M. Apoptotic signaling in skeletal muscle fibers during atrophy. Curr Opin Clin Nutr Metab Care. 2002;5(3):249&#x2013;253. doi: 10.1097/00075197-200205000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00075197-200205000-00003</ArticleId><ArticleId IdType="pubmed">11953649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, Fischbeck KH. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet. 2009;18(1):27&#x2013;42. doi: 10.1093/hmg/ddn310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn310</ArticleId><ArticleId IdType="pmc">PMC2644643</ArticleId><ArticleId IdType="pubmed">18824496</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold FJ, Pluciennik A, Merry DE. Impaired nuclear export of polyglutamine-expanded androgen receptor in spinal and bulbar muscular atrophy. Sci Rep. 2019;9(1):119. doi: 10.1038/s41598-018-36784-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-36784-4</ArticleId><ArticleId IdType="pmc">PMC6333819</ArticleId><ArticleId IdType="pubmed">30644418</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, Banno H, Takeuchi Y, Kawashima M, et al. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. J Neurol. 2019;266(5):1211&#x2013;1221. doi: 10.1007/s00415-019-09251-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09251-x</ArticleId><ArticleId IdType="pubmed">30847645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Hashizume A, Yamada S, Ito D, Banno H, Suzuki K, et al. Long-term effects of androgen deprivation in a patient with spinal and bulbar muscular atrophy - a case report with 14 years of follow-up. Intern Med. 2019;58(15):2231&#x2013;2234. doi: 10.2169/internalmedicine.1592-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.1592-18</ArticleId><ArticleId IdType="pmc">PMC6709315</ArticleId><ArticleId IdType="pubmed">30996158</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Yokota K, Amao R, Maeno T, Haga N, Taguri M, et al. An open trial of long-term testosterone suppression in spinal and bulbar muscular atrophy. Muscle Nerve. 2013;47(6):816&#x2013;822. doi: 10.1002/mus.23759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23759</ArticleId><ArticleId IdType="pubmed">23512333</ArticleId></ArticleIdList></Reference><Reference><Citation>Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, et al. Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer. 2014;21(4):T105&#x2013;118. doi: 10.1530/ERC-13-0545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-13-0545</ArticleId><ArticleId IdType="pubmed">24639562</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, et al. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem. 2006;98(4):770&#x2013;788. doi: 10.1002/jcb.20593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.20593</ArticleId><ArticleId IdType="pubmed">16440331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Rubinsztein DC. Small molecule enhancers of autophagy for neurodegenerative diseases. Mol Biosyst. 2008;4(9):895&#x2013;901. doi: 10.1039/b804606a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/b804606a</ArticleId><ArticleId IdType="pubmed">18704227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen S, Song L, Tang Y, Shen Y, Jia L, et al. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy. 2014;10(4):588&#x2013;602. doi: 10.4161/auto.27710.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.27710</ArticleId><ArticleId IdType="pmc">PMC4091147</ArticleId><ArticleId IdType="pubmed">24441414</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBosch BJ, Heitmeier MR, Mayer AL, Higgins CB, Crowley JR, Kraft TE, et al. Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis. Sci Signal. 2016;9(416):ra21. doi: 10.1126/scisignal.aac5472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aac5472</ArticleId><ArticleId IdType="pmc">PMC4816640</ArticleId><ArticleId IdType="pubmed">26905426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudmand-Hoyer E, Fenger HJ, Skovbjerg H, Kern-Hansen P, Madsen PR. Trehalase deficiency in Greenland. Scand J Gastroenterol. 1988;23(7):775&#x2013;778. doi: 10.3109/00365528809090759.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365528809090759</ArticleId><ArticleId IdType="pubmed">3227291</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath SR, Lieberman ML, Yu Z, Marchioretti C, Jones ST, Danby ECE, et al. MEF2 impairment underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathol. 2020;140(1):63&#x2013;80. doi: 10.1007/s00401-020-02156-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02156-4</ArticleId><ArticleId IdType="pmc">PMC7166004</ArticleId><ArticleId IdType="pubmed">32306066</ArticleId></ArticleIdList></Reference><Reference><Citation>Soraru G, D'Ascenzo C, Polo A, Palmieri A, Baggio L, Vergani L, et al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci. 2008;264(1&#x2013;2):100&#x2013;105. doi: 10.1016/j.jns.2007.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.08.012</ArticleId><ArticleId IdType="pubmed">17854832</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti D, Vescovini E, Motti L, Ghidoni E, Gemignani F, Marbini A, et al. X-linked bulbar and spinal muscular atrophy, or Kennedy disease: clinical, neurophysiological, neuropathological, neuropsychological and molecular study of a large family. J Neurol Sci. 1996;135(2):140&#x2013;148. doi: 10.1016/0022-510X(95)00283-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(95)00283-8</ArticleId><ArticleId IdType="pubmed">8867070</ArticleId></ArticleIdList></Reference><Reference><Citation>Malena A, Pennuto M, Tezze C, Querin G, D'Ascenzo C, Silani V, et al. Androgen-dependent impairment of myogenesis in spinal and bulbar muscular atrophy. Acta Neuropathol. 2013;126(1):109&#x2013;121. doi: 10.1007/s00401-013-1122-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1122-9</ArticleId><ArticleId IdType="pubmed">23644820</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiaffino S, Rossi AC, Smerdu V, Leinwand LA, Reggiani C. Developmental myosins: expression patterns and functional significance. Skelet Muscle. 2015;5:22. doi: 10.1186/s13395-015-0046-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13395-015-0046-6</ArticleId><ArticleId IdType="pmc">PMC4502549</ArticleId><ArticleId IdType="pubmed">26180627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E, et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab. 2002;87(8):3893&#x2013;3901.</Citation><ArticleIdList><ArticleId IdType="pubmed">12161529</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen ES, Merry DE. Testosterone treatment fails to accelerate disease in a transgenic mouse model of spinal and bulbar muscular atrophy. Dis Model Mech. 2012;5(1):141&#x2013;145. doi: 10.1242/dmm.007849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.007849</ArticleId><ArticleId IdType="pmc">PMC3255552</ArticleId><ArticleId IdType="pubmed">21954065</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Cristofani R, Galbiati M, Cicardi ME, Meroni M, Ferrari V, et al. The role of the heat shock protein B8 (HSPB8) in motoneuron diseases. Front Mol Neurosci. 2017;10:176. doi: 10.3389/fnmol.2017.00176.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00176</ArticleId><ArticleId IdType="pmc">PMC5478700</ArticleId><ArticleId IdType="pubmed">28680390</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Mishra A, Wakil S, Pennuto M, Soraru G. Mitochondrial implications in bulbospinal muscular atrophy (Kennedy disease) Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1&#x2013;2):112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">26428534</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgetti E, Yu Z, Chua JP, Shimamura R, Zhao L, Zhu F, et al. Rescue of metabolic alterations in AR113Q skeletal muscle by peripheral androgen receptor gene silencing. Cell Rep. 2016;17(1):125&#x2013;136. doi: 10.1016/j.celrep.2016.08.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.08.084</ArticleId><ArticleId IdType="pmc">PMC5076565</ArticleId><ArticleId IdType="pubmed">27681426</ArticleId></ArticleIdList></Reference><Reference><Citation>Vielhaber S, Kunz D, Winkler K, Wiedemann FR, Kirches E, Feistner H, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain. 2000;123(Pt 7):1339&#x2013;1348. doi: 10.1093/brain/123.7.1339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.7.1339</ArticleId><ArticleId IdType="pubmed">10869047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M, Martin LJ. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet. 2010;19(11):2284&#x2013;2302. doi: 10.1093/hmg/ddq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq106</ArticleId><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodavati M, Wang H, Hegde ML. Altered mitochondrial dynamics in motor neuron disease: an emerging perspective. Cells. 2020;9(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7226538</ArticleId><ArticleId IdType="pubmed">32344665</ArticleId></ArticleIdList></Reference><Reference><Citation>Tews DS. Muscle-fiber apoptosis in neuromuscular diseases. Muscle Nerve. 2005;32(4):443&#x2013;458. doi: 10.1002/mus.20348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20348</ArticleId><ArticleId IdType="pubmed">15937870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K, et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation. 1999;99(21):2757&#x2013;2764. doi: 10.1161/01.CIR.99.21.2757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.99.21.2757</ArticleId><ArticleId IdType="pubmed">10351969</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoser BG, Wehling S, Blottner D. Cell death and apoptosis-related proteins in muscle biopsies of sporadic amyotrophic lateral sclerosis and polyneuropathy. Muscle Nerve. 2001;24(8):1083&#x2013;1089. doi: 10.1002/mus.1114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.1114</ArticleId><ArticleId IdType="pubmed">11439385</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>